Related Experiment Video
Updated: Jun 12, 2026
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Acne rosacea associated imatinib mesylate in a gastrointestinal stromal tumor patient
Umut Demirci1, Ugur Coskun, Ozlem Erdem
1Department of Medical Oncology, Gazi University, Ankara, Turkey.
Abstract:
Tyrosine kinase inhibitors (TKIs) are targeted treatments for various cancers. Skin toxicities are one of the most common nonhematological side-effects of TKIs. We report an imatinib mesylate (IM) induced hyperpigmented acne rosacea (AR) and sunitinib-induced palmar hyperkeratosis in the case with gastrointestinal stromal tumor. AR was arisen due to the discontinuation of IM. To the best of our knowledge, this kind of cutaneous side-effect with IM has not been documented previously.
Insights
Tyrosine kinase inhibitors can cause skin side effects. This case report details imatinib-induced acne rosacea and sunitinib-induced palmar hyperkeratosis in a patient with gastrointestinal stromal tumor.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Tyrosine kinase inhibitors (TKIs) are crucial targeted therapies for various cancers.
- Skin toxicities are frequent nonhematological adverse events associated with TKI treatment.
- Understanding these side effects is vital for patient management and treatment adherence.
Observation:
- A patient with gastrointestinal stromal tumor experienced specific cutaneous side effects.
- These included hyperpigmented acne rosacea (AR) attributed to imatinib mesylate (IM) discontinuation.
- Palmar hyperkeratosis was observed during sunitinib treatment.
Findings:
- The case presents a novel association between imatinib mesylate and hyperpigmented acne rosacea.
- Acne rosacea developed following the cessation of imatinib therapy.
- Palmar hyperkeratosis was linked to sunitinib treatment.
Implications:
- This report highlights previously undocumented cutaneous side effects of imatinib.
- It underscores the importance of monitoring dermatological adverse events during TKI therapy.
- Further research may elucidate the mechanisms behind these specific TKI-induced skin reactions.
